On Apr. 16, 2020, Ihe International Vaccine Institute (IVI) announced that the Coalition for Epidemic Preparedness Innovations (CEPI) has granted $6.9 million funding to INOVIO to work with IVI and the Korea National Institute of Health (KNIH) for a Phase 1/2 clinical trial of INOVIO’s COVID-19 vaccine candidate (INO-4800) in South Korea.

IVI will conduct the trial in parallel to INOVIO’s Phase 1 INO-4800 study currently underway in the US since Apr. 6, 2020 with 40 healthy adults receiving the vaccine candidate and eventually expanding to older adults.